Destiny Pharma’s imminent Phase IIb study start dominated the FY18 results announcement. The US Phase IIb study of XF-73 is open and recruiting with results expected around YE19. Destiny’s operating loss increased to £6.1m (vs £3.2m in FY17) with R&D costs of £3.5m (vs £0.4m in FY17) comprising the majority of operational expense. Cash at the end of FY18 was £12.1m, which gives Destiny a runway well into 2020.
11 Apr 2019
Destiny Pharma - Well-funded with clinical results in a year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Destiny Pharma - Well-funded with clinical results in a year
Destiny Pharma Plc (DEST:LON) | 26.0 -0.4 (-5.5%) | Mkt Cap: 24.8m
- Published:
11 Apr 2019 -
Author:
Dr Andy Smith -
Pages:
5
Destiny Pharma’s imminent Phase IIb study start dominated the FY18 results announcement. The US Phase IIb study of XF-73 is open and recruiting with results expected around YE19. Destiny’s operating loss increased to £6.1m (vs £3.2m in FY17) with R&D costs of £3.5m (vs £0.4m in FY17) comprising the majority of operational expense. Cash at the end of FY18 was £12.1m, which gives Destiny a runway well into 2020.